Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22164327 | 0.94 | HSD11B1 (0.46) | HSD11B1TSHRHTTALDH1A1KDM4E | |
| SCHEMBL19717363 | 0.92 | HSD11B1 (0.45) | HSD11B1TSHRHTTALDH1A1KDM4E | |
| SCHEMBL28919252 | 0.87 | HSD11B1 (0.41) | HSD11B1TSHRHTTALDH1A1KDM4E | |
| SCHEMBL705057 | 0.86 | CYP1A2 (0.41) | HSD11B1TSHRHTTPOLBMAPK1 | |
| Bicarbonate SCHEMBL8660627 | 0.85 | ALDH1A1 (0.54) | HSD11B1TSHRHTTALDH1A1KDM4E | |
| SCHEMBL27580695 | 0.83 | HSD11B1 (0.52) | HSD11B1TSHRHTTALDH1A1KDM4E | |
| SCHEMBL4322770 | 0.81 | CYP1A2 (0.43) | ALDH1A1POLBMAPK1KMT2AGAA | |
| SCHEMBL4326132 | 0.81 | CYP1A2 (0.48) | ALDH1A1POLBMAPK1KMT2ACA12 | |
| Acetic Acid SCHEMBL9328243 | 0.80 | ALDH1A1 (0.50) | HSD11B1TSHRHTTALDH1A1KDM4E | |
| Acetic Acid SCHEMBL137819 | 0.80 | ALDH1A1 (0.50) | HSD11B1TSHRHTTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112368270-B | Pladienolide derivatives as spliceosome targeting agents for the treatment of cancer | 卫材R&D管理有限公司 | 2023-10-13 | — | — | CN | claimed |
| CN-113166091-A | Pladienolide compounds and uses thereof | 卫材R&D管理有限公司 | 2021-07-23 | — | — | CN | claimed |
| EP-2763978-B1 | CARBAMATE/ UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | NOVARTIS AG (CH) | 2017-02-01 | — | — | EP | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| CN-101312967-B | As 5-HT4Carbamate compounds of receptor agonists | THERAVANCE INC | 2011-08-24 | — | — | CN | claimed |
| EP-2066318-B1 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2010-05-12 | — | — | EP | claimed |
| US-7572794-B2 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER SCHERING PHARMA AG (DE) | 2009-08-11 | — | — | US | claimed |
| EP-2066318-A2 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | claimed |
| CN-101312967-A | As 5-HT4Carbamate compounds of receptor agonists | THERAVANCE INC (US) | 2008-11-26 | — | — | CN | claimed |
| WO-2008034736-A2 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | WO | claimed |
| CN-101056871-A | Novel anthranilamide pyridinureas as vegf receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2007-10-17 | — | — | CN | claimed |
| US-20060264425-A1 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-23 | — | — | US | claimed |
| EP-1657241-A1 | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors | Schering Aktiengesellschaft (DE) | 2006-05-17 | — | — | EP | claimed |
| EP-0593227-B1 | Carbamates of rapamycin | WYETH CORP (US) | 2006-03-22 | — | — | EP | claimed |
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | claimed |
| EP-1266900-A1 | Carbamates of rapamycin | Wyeth (US) | 2002-12-18 | — | — | EP | claimed |
| US-5530121-A | IMMUNOSUPPRESSANTS, ANTIINFLAMMATORY AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-06-25 | — | — | US | claimed |
| EP-0593227-A1 | Carbamates of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-04-20 | — | — | EP | claimed |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
| US-20240217988-A1 | ESTROGEN RECEPTOR ANTAGONIST | SHENZHEN FORWARD PHARMACEUTICALS CO., LIMITED (CN) | 2024-07-04 | — | — | US | disclosed |
| WO-2024085699-A1 | COMPOUND FOR SHP2 PROTEIN DEGRADATION AND MEDICAL USES THEREOF | 주식회사 유빅스테라퓨틱스 | 2024-04-25 | — | — | WO | disclosed |
| EP-4310079-A1 | ESTROGEN RECEPTOR ANTAGONIST | Shenzhen Forward Pharmaceuticals Co., Limited (CN) | 2024-01-24 | — | — | EP | disclosed |
| US-11873283-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| CN-117285502-A | Pladienolide derivatives as spliceosome targeting agents for the treatment of cancer | 卫材R&D管理有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20230390404-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | TREELINE BIOSCIENCES INC (US) | 2023-12-07 | — | — | US | disclosed |
| CN-112368270-B | Pladienolide derivatives as spliceosome targeting agents for the treatment of cancer | 卫材R&D管理有限公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2023177356-A2 | COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2023-09-21 | — | — | WO | disclosed |
| US-20230159537-A1 | COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | TIANJIN JIKUN MEDICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| CN-116096719-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4168002-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2023-04-26 | — | — | EP | disclosed |
| EP-4116302-A1 | COMPOUND AND PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN PREPARATION OF THERAPEUTIC ANTI-CANCER DRUG | Tianjin Jikun Medical Technology Co., Ltd. (CN) | 2023-01-11 | — | — | EP | disclosed |
| US-20230002321-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | CELGENE CORP (US) | 2023-01-05 | — | — | US | disclosed |
| CN-115232111-A | SOS1 degradation agent and preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-114728076-A | MCL-1 inhibitor antibody-drug conjugates and methods of use | 诺华股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021122415-A9 | FUROINDAZOLE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022017442-A1 | BIFUNCTIONAL PROTEIN DEGRADATION-TARGETED CHIMERA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICINAL USE THEREOF | 恩瑞生物医药科技（上海）有限公司 | 2022-01-27 | — | — | WO | disclosed |
| WO-2021257736-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2021-12-23 | — | — | WO | disclosed |
| EP-3920923-A2 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | University of Florida Research Foundation, Incorporated (US) | 2021-12-15 | — | — | EP | disclosed |
| US-11149007-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | CELGENE CORPORATION (US) | 2021-10-19 | — | — | US | disclosed |
| CN-113166091-A | Pladienolide compounds and uses thereof | 卫材R&D管理有限公司 | 2021-07-23 | — | — | CN | disclosed |
| US-10844076-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | NEKTAR THERAPEUTICS (US) | 2020-11-24 | — | — | US | disclosed |
| EP-3727355-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | AstraZeneca AB (SE) | 2020-10-28 | — | — | EP | disclosed |
| WO-2020192581-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | 首药控股(北京)有限公司 | 2020-10-01 | — | — | WO | disclosed |
| WO-2020168172-A1 | CONJUGATE COMPOUNDS FOR THE DEGRADATION OF RAF | ZAMBONI CHEM SOLUTIONS INC. (CA) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020163823-A2 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200199073-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2020-06-25 | — | — | US | disclosed |
| US-20190071454-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | NEKTAR THERAPEUTICS | 2019-03-07 | — | — | US | disclosed |
| EP-3442973-A1 | NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Legochem Bioscience Ltd. (KR) | 2019-02-20 | — | — | EP | disclosed |
| US-10189859-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | NEKTAR THERAPEUTICS (US) | 2019-01-29 | — | — | US | disclosed |
| WO-2018212534-A1 | NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LEGOCHEM BIOSCIENCES, INC. (KR) | 2018-11-22 | — | — | WO | disclosed |
| US-20180155340-A1 | QUINOLONE DERIVATIVES AS FGFR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2018-06-07 | — | — | US | disclosed |
| US-20170066782-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | NEKTAR THERAPEUTICS | 2017-03-09 | — | — | US | disclosed |
| EP-3134125-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | Pierre Fabre Médicament (FR) | 2017-03-01 | — | — | EP | disclosed |
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| EP-2989086-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | Pierre Fabre Médicament (FR) | 2016-03-02 | — | — | EP | disclosed |
| WO-2015162293-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2015-10-29 | — | — | WO | disclosed |
| US-9169259-B2 | Imidazopyridazine compounds | HOFFMANN-LA ROCHE INC. (US) | 2015-10-27 | — | — | US | disclosed |
| WO-2015106294-A1 | BIVALENT BCR-ABL TYROSINE KINASE LIGANDS, AND METHODS OF USING SAME | COFERON,INC. (US) | 2015-07-16 | — | — | WO | disclosed |
| US-8933012-B2 | Glycopeptide antibiotic derivative | SHIONOGI & CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| WO-2014174060-A1 | DERIVATIVES OF DOLASTATIN 10 AND AURISTATINS | PIERRE FABRE MEDICAMENT (FR) | 2014-10-30 | — | — | WO | disclosed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | disclosed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | disclosed |
| EP-2773645-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| CN-104024261-A | Imidazopyridazine compounds | HOFFMANN LA ROCHE | 2014-09-03 | — | — | CN | disclosed |
| WO-2013064445-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-10 | — | — | WO | disclosed |
| US-20130109661-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| EP-2234992-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-02-22 | — | — | EP | disclosed |
| US-8093248-B2 | Compounds useful for the treatment of conditions associated with weight gain | ASTRAZENECA AB (PUBL) (SE) | 2012-01-10 | — | — | US | disclosed |
| US-20110275638-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | disclosed |
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | disclosed |
| CN-101312967-B | As 5-HT4Carbamate compounds of receptor agonists | THERAVANCE INC | 2011-08-24 | — | — | CN | disclosed |
| EP-2326327-A2 | ANALOGS OF INDOLE-3-CARBINOL AND THEIR USE AS AGENTS AGAINST INFECTION | SRI International (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-2310368-A1 | SMALL MOLECULE LEPTIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2234992-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2010-10-06 | — | — | EP | disclosed |
| CN-101723948-A | C-6 modified indazolylpyrrolotriazines | BRISTOL MYERS SQUIBB CO | 2010-06-09 | — | — | CN | disclosed |
| EP-2066318-B1 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2010-05-12 | — | — | EP | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010033198-A2 | ANALOGS OF INDOLE-3-CARBINOL AND THEIR USE AS AGENTS AGAINST INFECTION | SRI INTERNATIONAL (US) | 2010-03-25 | — | — | WO | disclosed |
| EP-1789404-B1 | SUBSTITUTED N-ARYLSULFONYLHETEROCYCLIC AMINES AS GAMMA-SECRETASE INHIBITORS | SCHERING CORP (US) | 2010-03-24 | — | — | EP | disclosed |
| US-20100029641-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2009155606-A1 | ANTICANCER COMPOUNDS AND METHODS OF MAKING AND USING SAME | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009147221-A1 | SMALL MOLECULE LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-12-10 | — | — | WO | disclosed |
| US-20090286717-A1 | Glycopeptide Antibiotic Derivative | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090281087-A1 | Compounds II | BIOVITRUM AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-7601722-B2 | Aryl sulfamide derivatives and methods of their use | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| US-7572794-B2 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER SCHERING PHARMA AG (DE) | 2009-08-11 | — | — | US | disclosed |
| US-7557110-B2 | MAPKAP-K2; inflammatory disease, autoimmune disease, destructive bone disorder, cancer and/or tumour growth; 5-[(trans-4-aminocyclohexyl)amino]-3-fluoro-6-methyl(pyrazolo[1,5-a]pyri- midin-7-yl)}(4-iodophenyl)amine | TEIJIN PHARMA LIMITED (JP) | 2009-07-07 | — | — | US | disclosed |
| WO-2009071668-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | BIOVITRUM AB (PUBL) (SE) | 2009-06-11 | — | — | WO | disclosed |
| EP-2066318-A2 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | F. Hoffmann-Roche AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| EP-2061776-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | Wyeth a Corporation of the State of Delaware (US) | 2009-05-27 | — | — | EP | disclosed |
| CN-101381379-A | Kinase inhibitor phosphonate conjugates | GILEAD SCIENCES INC (US) | 2009-03-11 | — | — | CN | disclosed |
| EP-2030982-A1 | GLYCOPEPTIDE ANTIBIOTIC DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2009-03-04 | — | — | EP | disclosed |
| CN-101312967-A | As 5-HT4Carbamate compounds of receptor agonists | THERAVANCE INC (US) | 2008-11-26 | — | — | CN | disclosed |
| EP-1599482-A4 | PYRAZOLO 1,5-A PYRIMIDINE DERIVATIVES | TEIJIN PHARMA LTD (JP) | 2008-10-01 | — | — | EP | disclosed |
| EP-1957460-A1 | BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-08-20 | — | — | EP | disclosed |
| US-20080167303-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008073459-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008034736-A2 | OXINDOLE DERIVATIVES AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-03-27 | — | — | WO | disclosed |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | ICAGEN, INC. (US) | 2008-03-13 | — | — | US | disclosed |
| CN-101056871-A | Novel anthranilamide pyridinureas as vegf receptor kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2007-10-17 | — | — | CN | disclosed |
| EP-1807415-A2 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-07-18 | — | — | EP | disclosed |
| CN-1326519-C | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2007-07-18 | — | — | CN | disclosed |
| WO-2007067444-A1 | BICYCLIC COMPOUNDS WITH KINASE INHIBITORY ACTIVITY | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
| US-7223782-B2 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20060264425-A1 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-23 | — | — | US | disclosed |
| US-20060189632-A1 | Pyrazolo[1,5-A] pyrimidine derivatives | TEIJIN PHARMA LIMITED (JP) | 2006-08-24 | — | — | US | disclosed |
| CN-1819832-A | Kinase inhibitory phosphonate analogs | GILEAD SCIENCES INC (US) | 2006-08-16 | — | — | CN | disclosed |
| CN-1780631-A | anticancer phosphonate analogs | GILEAD SCIENCES INC (US) | 2006-05-31 | — | — | CN | disclosed |
| US-7053114-B2 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1657241-A1 | Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors | Schering Aktiengesellschaft (DE) | 2006-05-17 | — | — | EP | disclosed |
| WO-2006048248-A2 | NOVEL ANTHRANILAMIDE PYRIDINUREAS AS VEGF RECEPTOR KINASE IMHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-05-11 | — | — | WO | disclosed |
| EP-0593227-B1 | Carbamates of rapamycin | WYETH CORP (US) | 2006-03-22 | — | — | EP | disclosed |
| CN-1726216-A | C-6 modified indazolylpyrrolotriazines | BRISTOL MYERS SQUIBB CO (US) | 2006-01-25 | — | — | CN | disclosed |
| EP-1599482-A1 | PYRAZOLO 1,5-A PYRIMIDINE DERIVATIVES | Teijin Pharma Limited (JP) | 2005-11-30 | — | — | EP | disclosed |
| US-20050209195-A1 | Indolinone derivatives | CELL THERAPEUTICS EUROPE S.R.I (IT) | 2005-09-22 | — | — | US | disclosed |
| WO-2005068424-A1 | INDOLINONE DERIVATIVES AS RECEPTOR TYROSINE KINASE IHIBITORS | CELL THERAPEUTICS EUROPE S.R.L. (IT) | 2005-07-28 | — | — | WO | disclosed |
| CN-1602191-A | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK AS (DK) | 2005-03-30 | — | — | CN | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
| US-6797725-B2 | SUCH AS 4-METHYL-5-(2-OXO-1,2-DIHYDROINDOL-3-YLILDENEMETHYL)-1H-PYRROLE-2-CARBOXYLIC ACID FOR PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED CELLULAR DISORDERS; ANTICANCER AGENTS | SUGEN, INC. | 2004-09-28 | — | — | US | disclosed |
| US-20040186161-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004076458-A1 | PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES | TEIJIN PHARMA LIMITED (JP) | 2004-09-10 | — | — | WO | disclosed |
| CN-1147483-C | Adamantane derivative | — | 2004-04-28 | — | — | CN | disclosed |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN. INC. | 2003-05-29 | — | — | US | disclosed |
| EP-1266900-A1 | Carbamates of rapamycin | Wyeth (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6492355-B1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2002-12-10 | — | — | US | disclosed |
| WO-2002081466-A1 | PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES | SUGEN, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| CN-1353702-A | Adamantane derivative | ASTRAZENECA AB (SE) | 2002-06-12 | — | — | CN | disclosed |
| EP-1171432-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000061569-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-10-19 | — | — | WO | disclosed |
| EP-0815103-A1 | TRYPSIN AND THROMBIN INHIBITORS | Novartis AG (CH) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996029327-A1 | TRYPSIN AND THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1996-09-26 | — | — | WO | disclosed |
| US-5559120-A | IMMUNOSUPPRESSANTS, ANTIINFLAMMATORY AGENTS, FUNGICIDES AND ANTITUMOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| US-5530121-A | IMMUNOSUPPRESSANTS, ANTIINFLAMMATORY AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-06-25 | — | — | US | disclosed |
| US-5530007-A | ANTITUMOR, ANTIINFLAMMATORY, ANTIFUNGAL, ANTIPROLIFERATIVE, IMMUNOSUPPRESSIVE AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-06-25 | — | — | US | disclosed |
| US-5508399-A | USEFUL AS IMMUNOSUPPRESSANT, ANTIINFLAMMATORY, ANTIFUNGAL, ANTIPROLIFERATIVE AND ANTIUMOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-04-16 | — | — | US | disclosed |
| US-5480989-A | Carbamates of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-01-02 | — | — | US | disclosed |
| US-5411967-A | Antiinflammatory, immunosuppressant, antitumor | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-05-02 | — | — | US | disclosed |
| EP-0593227-A1 | Carbamates of rapamycin | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-04-20 | — | — | EP | disclosed |
| US-5302584-A | Immunosuppressants | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-04-12 | — | — | US | disclosed |
| US-5302584-A | Immunosuppressants | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (28 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029641-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | HSD11B1 112/4885TSHR 2073/4885HTT 392/4885 |
| US-20230002321-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AR, NR5A2, ESRRA | HSD11B1 953/4885TSHR 328/4885HTT 1572/4885 |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | HSD11B1 2132/4885TSHR 1947/4885HTT 2002/4885 |
| US-20180155340-A1 | QUINOLONE DERIVATIVES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | HSD11B1 3165/4885TSHR 3940/4885HTT 3265/4885 |
| US-10844076-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | KCNJ2, TRPC5, RYR2 | HSD11B1 4870/4885TSHR 508/4885HTT 921/4885 |
| US-20040186161-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | HSD11B1 3389/4885TSHR 2616/4885HTT 3768/4885 |
| US-11873283-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | AR, NR5A2, ESRRA | HSD11B1 953/4885TSHR 328/4885HTT 1572/4885 |
| US-20230159537-A1 | COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG | FGFR1, FGFR3, FGFR4 | HSD11B1 2538/4885TSHR 4216/4885HTT 2448/4885 |
| US-20240217988-A1 | ESTROGEN RECEPTOR ANTAGONIST | GPER1, ESR1, ESR2 | HSD11B1 83/4885TSHR 97/4885HTT 1915/4885 |
| US-20190071454-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | KCNJ2, TRPC5, RYR2 | HSD11B1 4870/4885TSHR 508/4885HTT 921/4885 |
| US-20080064690-A1 | PYRAZOLE-AMIDES AND -SULFONAMIDES | SCN3A, TRPV3, HCN3 | HSD11B1 4450/4885TSHR 3666/4885HTT 2539/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | HSD11B1 4450/4885TSHR 3666/4885HTT 2539/4885 |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | HSD11B1 453/4885TSHR 2673/4885HTT 900/4885 |
| US-11149007-B2 | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith | AR, NR5A2, ESRRA | HSD11B1 953/4885TSHR 328/4885HTT 1572/4885 |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | HSD11B1 3389/4885TSHR 2616/4885HTT 3768/4885 |
| US-20110275638-A1 | PIPERAZINE DERIVATIVES AND THEIR USE AS LEPTIN RECEPTOR MODULATORS | ADIPOR2, GPR119, ADIPOR1 | HSD11B1 2540/4885TSHR 241/4885HTT 3444/4885 |
| US-20170066782-A1 | DERIVATIVES OF 6-(2,3-DICHLOROPHENYL)-1,2,4-TRIAZIN-5-AMINE | KCNJ2, TRPC5, RYR2 | HSD11B1 4870/4885TSHR 508/4885HTT 921/4885 |
| US-20090286717-A1 | Glycopeptide Antibiotic Derivative | NR2C2, NR0B2, NR3C2 | HSD11B1 215/4885TSHR 138/4885HTT 3421/4885 |
| US-20200199073-A1 | SUBSTITUTED 3-((3-AMINOPHENYL)AMINO)PIPERIDINE-2,6-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | AR, NR5A2, ESRRA | HSD11B1 953/4885TSHR 328/4885HTT 1572/4885 |
| US-10189859-B2 | Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine | KCNJ2, TRPC5, RYR2 | HSD11B1 4870/4885TSHR 508/4885HTT 921/4885 |
| US-20060264425-A1 | 4-hydroxy-4-methyl-piperidine-1 -carboxylic acid (4-{[2-(2-methyl-2H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide; 2,6-dimethyl-morpholine-4-carboxylic acid (4-{[2-(1-methyl-1H-indazol-6-ylcarbamoyl)-phenylamino]-methyl}-pyridin-2-yl)-amide | KDR, FLT4, FLT1 | HSD11B1 4807/4885TSHR 1869/4885HTT 2388/4885 |
| US-20080167303-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | HSD11B1 112/4885TSHR 2073/4885HTT 392/4885 |
| US-20050209195-A1 | Indolinone derivatives | RET, MET, FGFR1 | HSD11B1 3620/4885TSHR 975/4885HTT 3372/4885 |
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | HSD11B1 2940/4885TSHR 4074/4885HTT 889/4885 |
| US-20230390404-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | HSD11B1 2940/4885TSHR 4074/4885HTT 889/4885 |
| US-20090281087-A1 | Compounds II | GPR119, FABP4, LIPC | HSD11B1 551/4885TSHR 357/4885HTT 3647/4885 |
| US-20130109661-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | SYK, BTK, IRAK4 | HSD11B1 1931/4885TSHR 3492/4885HTT 4818/4885 |
| US-20060189632-A1 | Pyrazolo[1,5-A] pyrimidine derivatives | MAP3K1, MAP3K5, MAP3K15 | HSD11B1 4178/4885TSHR 2648/4885HTT 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.